Efficiency of energy-rich therapy for cellular energy metabolic disturbances in children with mitral valve prolapse
https://doi.org/10.21508/1027-4065-2017-62-1-74-80
Abstract
Objective: to determine impairments in cell energy metabolism (the levels of amino acids and carnitine) in children with connective tissue dysplasia, such as mitral valve prolapse, and to evaluate the efficiency of energy-rich therapy.
Subjects and methods. High-performance liquid chromatography- mass spectrometry was used to determine the levels of carnitines and amino acids in dried blood spots from 57 children with mitral valve prolapse (1–2 variants without regurgitation) and in 38 children having Health Groups 1 and 2. The clinical efficiency of prolonged (12-month) combined use of energy-rich medications (L-carnitine, coenzyme Q10) was evaluated.
Results. As compared with the controls, the children with mitral valve prolapse showed a significant change, although not beyond the normal range, in the values of free and bound carnitine and amino acids (primarily methionine). There was a significant increase of these indicators in the blood during 12-month combined energy-rich therapy.
Conclusion. The findings suggest that that there are moderate, but significant tissue metabolic changes in children with mitral valve prolapse. The found changes are a rationale for the use of energy-rich therapy in this category of children. Analysis of dried blood spots by liquid chromatography tandem mass spectrometry is recommended for the early diagnosis of cellular energy metabolic disturbances in children with signs of connective tissue dysplasia, such as mitral valve prolapse.
About the Authors
M. T. BaedilovaRussian Federation
V. V. Sumenko
Russian Federation
V. S. Sukhorukov
Russian Federation
S. E. Lebedkova
Russian Federation
O. V. Trusova
Russian Federation
References
1. Сухоруков В.С. Очерки митохондриальной патологии. М: ИД «МЕДПРАКТИКА-М», 2011; 288. [Sukhorukov V.S. Essays mitochondrial pathology. Moscow: ID “MEDPRAKTIKA-M”, 2011; 288. (in Russ)]
2. Кадурина Т.И., Гнусаев С.Ф., Аббакумова Л.Н., Алимова И.Л., Антонова Н.С., Апенченко Ю.С. и др. Наследственные и многофакторные нарушения соединительной ткани у детей, алгоритмы диагностики. Тактика ведения. Проект российских рекомендаций разработан комитетом экспертов педиатрической группы «Дисплазия соединительной ткани» при российском научном обществе терапевтов. Медицинский вестник Северного Кавказа 2015; 10: 1 (37): 5–35. [Kadurina T.I., Gnusaev S.F., Abbakumova L.N., Alimova I.L., Antonova N.S., Apenchenko Yu.S. et al. Multi-factor hereditary disorders of connective tissue in children. diagnostic algorithms. Tactics of conducting. Russian Draft recommendations developed by the Expert Committee of the pediatric group “Dysplasia of connective tissue” in the Russian Scientific Society of Physicians. Meditsinskij vestnik Severnogo Kavkaza 2015; 10: 1 (37): 5–35. (in Russ)]
3. Семячкина А.Н., Николаева Е.А., Семячкина С.В., Сухоруков В.С., Сафронова О.Н., Новиков П.В. Медикаментозная коррекция нарушений клеточной биоэнергетики у больных с моногенными заболеваниями соединительной ткани. Педиатрическая фармакология 2003; 1: (1): 41–44. [Semyachkina A.N., Nikolaeva E.A., Semyachkina S.V., Sukhorukov V.S., Safronov O.N., Novikov P.V. Medicamentous correction of cellular bioenergy disorders in patients with monogenic connective-tissue diseases. Pediatricheskaya farmakologiya 2003; 1: (1): 41–44. (in Russ)]
4. Демин В.Ф., Ключников С.О., Ключникова М.А. Значение соединительнотканных дисплазий в патологии детского возраста. Вопр соврем педиатр 2005; (1): 50–56. [Demin V.F., Kluchnikov S.O., Klyuchnikova M.A. Meaning of connective tissue dysplasia in childhood disease. Current pediatrics 2005; (1): 50–56. (in Russ)]
5. Нечаева Г., Викторова И., Друк И. Дисплазия соединительной ткани: распространенность, фенотипические признаки, ассоциации с другими заболеваниями. Врач 2006; (1): 19–23. [Nechayeva G., Viktorova I., Druk I. Connective tissue dysplasia: incidence, phenotypic traits, association with other diseases. Vrach 2006; (1): 19–23. (in Russ)]
6. Леонтьева И.В., Лебедькова С.Е. Миокардиодистрофия у детей и подростков. М: Медицина 2010; 113. [Leont’eva I.V., Lebed’kova S.E. Myocardiodistrophy in children and adolescents. Moscow: Meditsina 2010; 113. (in Russ)]
7. Белозеров Ю.М., Османов И.М., Магомедова Ш.М. Проблема пролапса митрального клапана у детей и подростков. Рос вестн перинатол и педиатр 2009; (4): 15–23. [Belozerov Yu.M., Osmanov I.M., Magomedova Sh.M. The problem of mitral valve prolapse in children and adolescents. Ros vestn perinatol i pediatr 2009; (4): 15–23. (in Russ)]
8. Оганов Р.Г. Лебедькова С.Е., Челпаченко О.Е., Суменко В.В. Дисплазии соединительной ткани. М 2009; 219. [Oganov R.G., Lebed’kova S.E., Chelpachenko O.E., Sumenko V.V. Dysplasia of connective tissue. Moscow, 2009; 219. (in Russ)]
9. Гринио Л.П. Коэнзим Q10 в клинической практике. Библиотека практикующего врача. М: Медицина 2006; 120. [Grenio L.P. Coenzyme Q10 in clinical practice. Library practitioner. Moscow: Meditsina 2006; 120. (in Russ)]
10. Брин И.Л. Элькар (20% раствор L-карнитина) в педиатрии. Научный обзор. М 2005; 36. [Brin I.L., Elkar (20% solution of L-carnitine) in pediatrics. Scientific review. Moscow 2005; 36. (in Russ)]
11. Ключников С.О., Ильяшенко Д.А., Ключников М.С. Обоснование применения L- карнитина и коэнзима Q10 у подростков. Вопр соврем педиатр 2008; 7: (4): 102–104. [Kluchnikov S.O., Ilyashenko D.A., Kluchnikov M.S. Reasonable treatment of adolescents with L-carnitine and coenzyme Q10. Current pediatrics 2008; 7: (4): 102–104. (in Russ)]
12. Баедилова М.Т., Лебедькова С.Е., Суменко В.В., Рощупкин А.Н., Сухоруков В.С., Трусова О.Ю. и др. Клиническая эффективность энерготропной терапии у детей с синдромом хронической усталости при дисплазии соединительной ткани. Медицинский вестник Северного Кавказа 2016; (11): 2–2: 294–298. [Baedilova M.T., Lebed’kova S.E., Sumenko V.V., Roshchupkin A.N., Suhorukov V.S., Trusova O.Yu. et al. Clinical efficacy energotrophic therapy in children with chronic fatigue syndrome with connective tissue dysplasia. Meditsinskij vestnik Severnogo Kavkaza 2016; (11): 2–2: 294–298. (in Russ)]
13. Сухоруков В.С., Золкина И.В., Мамедов И.С., Глаговский П.Б. Оценка показателей карнитинового и аминокислотного обмена у детей с врожденными пороками сердца. Лабораторная служба 2015; (1): 16–19. [Sukhorukov V.S., Zolkina I.V., Mamedov I.S., Glagovsky P.B. Estimation of the carnitine, and amino acid metabolism in children with congenital heart disease. Laboratornaya sluzhba 2015; (1): 16–19. (in Russ)]
Review
For citations:
Baedilova M.T., Sumenko V.V., Sukhorukov V.S., Lebedkova S.E., Trusova O.V. Efficiency of energy-rich therapy for cellular energy metabolic disturbances in children with mitral valve prolapse. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2017;62(1):74-80. (In Russ.) https://doi.org/10.21508/1027-4065-2017-62-1-74-80